What's happening
The bill requires newborn screening for adrenoleukodystrophy and glucose-6-phosphate dehydrogenase deficiency in New York.
Why it matters
Early detection of serious genetic conditions. By mandating newborn screening for adrenoleukodystrophy (ALD) and glucose-6-phosphate dehydrogenase (G6PD) deficiency, the bill aims to catch these potentially life-threatening or disabling disorders before symptoms appear, allowing for timely intervention and better long-term outcomes.
Increased equity in healthcare. Standardizing the inclusion of ALD and G6PD tests ensures that all newborns in New York, regardless of hospital or region, are screened for these conditions, reducing disparities in early diagnosis and treatment access.
Potential to reduce long-term healthcare costs and burdens. Early identification of ALD and G6PD deficiency can prevent serious complications that require expensive, prolonged treatment or hospitalization, benefiting both families and the healthcare system.
Empowering families with critical health information. Parents will receive vital information about their child’s health status soon after birth, enabling informed medical decisions and, in the case of positive results, early connection to necessary support and resources.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Who cares
Hospitals and other institutions caring for newborns
The bill would explicitly require screening for adrenoleukodystrophy and glucose-6-phosphate dehydrogenase deficiency alongside the other listed conditions.
Parents and guardians of newborns
The bill would place both conditions on the required screening list while retaining the existing religious exemption from testing.
New York State health commissioner
The bill would require regulations and other actions needed to implement the changes by the effective date, 180 days after becoming law.
Wadsworth Center
The bill would remove the provision tying the addition of adrenoleukodystrophy screening to the center’s validation of a test and instead list the condition directly in law.
Headline styles
Expand Newborn Disease Screening
Plain English, a few words. Used as the page title.
Sponsors
3 Co-sponsors
History
- Substituted by A4572
- Advanced to third reading
- 2nd report cal.
- 1st report cal.722
- Reported and committed to finance
- Referred to health
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Expand Newborn Disease Screening
Signed by Governor · Sponsor Richard Gottfried
Full text
2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
4316
2021-2022 Regular Sessions
IN SENATE
February 3, 2021
Introduced by Sen. RIVERA -- read twice and ordered printed, and when printed to be committed to the Committee on Health
AN ACT to amend the public health law, in relation to newborn screening for adrenoleukodystrophy and glucose-6-phosphate dehydrogenase deficiency
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Section 2500-a of the public health law, as separately amended by chapters 943 and 1016 of the laws of 1974, subdivision (a) as amended by chapter 307 of the laws of 2018 and subdivision (c) as added by section 113 of part E of chapter 56 of the laws of 2013, is amended to read as follows:
§ 2500-a. Test for phenylketonuria and other diseases and conditions. [(a)] 1. It shall be the duty of the administrative officer or other person in charge of each institution caring for infants twenty-eight days or less of age and the person required in pursuance of the provisions of section forty-one hundred thirty of this chapter to register the birth of a child, to cause to have administered to every such infant or child in its or his care a test for diseases and conditions designated by the commissioner under regulations of the commissioner, and for:
[i. phenylketonuria,
ii. homozygous sickle cell disease,
iii. hypothyroidism,
iv. branched-chain ketonuria,
v. galactosemia,
vi. homocystinuria,
vii. critical congenital heart defects through pulse oximetry screening,
viii. with] (a) Phenylketonuria.
(b) Homozygous sickle cell disease.
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD00136-01-1
S. 4316 2
(c) Hypothyroidism.
(d) Branched-chain ketonuria.
(e) Galactosemia.
(f) Homocystinuria.
(g) Critical congenital heart defects through pulse oximetry screening.
(h) With regard to any newborn infant who is identified as, or suspected of, having a hearing impairment as a result of a screening conducted pursuant to section twenty-five hundred-g of this title, [cause to be administered to such infant] a urine polymerase chain reaction (PCR) test for cytomegalovirus, unless the parent of the infant objects thereto; provided that if the commissioner determines that another test for cytomegalovirus is diagnostically equivalent to or better than the urine polymerase chain reaction test, the commissioner may, by regulation under this section, allow or require the use of that other test[, and
ix. such other diseases and conditions as may from time to time be designated by the commissioner in accordance with rules or regulations prescribed by the commissioner].
(i) Adrenoleukodystrophy.
(j) Glucose-6-phosphate dehydrogenase deficiency.
2. Testing, the recording of the results of such tests, tracking, follow-up reviews and educational activities shall be performed at such times and in such manner as may be prescribed by the commissioner. The commissioner shall promulgate regulations setting forth the manner in which information describing the purposes of the requirements of this section shall be disseminated to parents or a guardian of the infant tested.
[(b)] 3. The provisions of this section shall not apply in the case of any infant or child whose parent or guardian is a member of a recognized religious organization whose teachings and tenets are contrary to the testing herein required and who notifies the person charged with having such test administered of his objection thereto.
[(c) By regulation, the commissioner shall add adrenoleukodystrophy ("ALD") to the list of diseases and conditions for which testing shall be performed pursuant to subdivision (a) of this section upon validation by the Wadsworth Center of a test for ALD. The Wadsworth Center shall undertake the process for validation upon the development of a test. This subdivision shall be known and may be cited as "Aidan's Law."]
§ 2. This act shall take effect on the one hundred eightieth day after it shall have become a law. Effective immediately, the commissioner of health shall make regulations and take other actions reasonably necessary to implement this act on that date.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Sponsor's memo
Title of bill
An act to amend the public health law, in relation to newborn screening for adrenoleukodystrophy and glucose-6-phosphate dehydrogenase deficien- cy
Purpose or general idea of bill
To add
glucose-6-phosphate dehydrogenase deficiency to the list of conditions that all newborns are screened for.
Summary of provisions
Section 1 amends Public Health Law § 2500-a to add glucose-6-phosphate dehydrogenase deficiency to the list of conditions that all newborns are screened for. This section also includes technical cleanup to make the section clearer and format it in line with the rest of the Public Health Law. It removes subdivision 2 paragraph (c), which required the Deparm- tent of Health to add testing for adrenoleukodystrophy after conducting a validation process, because the Wadsworth Center has already completed that validation process, so it adds adrenoleukodystrophy to the screen- ing list.
§ 2. Takes effect 180 days after it becomes a law. Effective immediate- ly, the Health Commissioner shall make regulations and take other actions reasonably necessary to implement this act on that date
Justification
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an inherited genetic enzyme disorder that affects the functioning of red blood cells and has the potential to cause attacks of acute hemolytic anemia, severe neonatal jaundice that can lead to hyperbilirubinemia (a high concen- tration of bilirubin in the blood) and kernicterus (where the bilirubin crosses the blood-brain barrier and affects the developing brain), and, more rarely, chronic anemia called chronic non-spherocytic hemolytic anemia (CNSHA). In the most severe cases, untreated G6PD deficiency leads to permanent brain damage and sometimes death. It also weakens the immune system, and recent studies suggest it leaves those affected more vulnerable to COVID-19.
If a newborn is known to have G6PD deficiency, the newborn can be checked for bilirubin before it reaches harmful levels, which often occurs after the newborn leaves the hospital but before the first pedia- trician visit. Certain foods and drugs are known to trigger symptoms of G6PD, and the simplest treatment is avoiding them. But since screening for G6PD deficiency is not common practice and most carriers do not know they carry it, families and health care providers are often unaware of the triggers and do not consider checking bilirubin levels until damage has already been done. Prevalence of the deficiency is highest in popu- lations from suk;Saharan Africa, the Mediterranean, and Southeast Asia. It is thought to occur at a rateabetWeen 4-7% in the United States, and the World Health Organization (WHO) says that any genetic disorder with a prevalence of above 3% in the population should be universally screened. The Newborn Screening and Molecular Biology Branch of the CDC provides technical laboratory support for state newborn screening programs and has an existing technical program to support screening for G6PD deficiency. A state as ethnically diverse as New York should be screening all newborns for G6PD deficiency to ensure that newborns with the condition receive the care they need and avoid potentially lethal complications.
Prior legislative history
New bill
Fiscal implications for state and local governments
Negligible. Considerable savings from avoiding costly treatment and care if the condition is identified early.
Effective date
This act shall take effect on the one hundred eightieth day after it shall have become a law. Effective immediately, the commissioner of health shall make regulations and take other actions reasonably neces- sary to implement this act on that date.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.